Home
About Us
Our Team
Our Values
Our Science
Pipeline
R&D Platforms
Your Health
Therapeutic Areas
Guide to Clinical Trials
Find a Trial
News
Contact Us
Join ScinnoHub
Partnership
中
Home
About Us
Our Team
Our Values
Our Science
Pipeline
R&D Platforms
Your Health
Therapeutic Areas
Guide to Clinical Trials
Find a Trial
News
Contact Us
Join ScinnoHub
Partnership
Our Science
Pipeline
R&D Platforms
Home
>
Our Science
>
Pipeline
Program
Mechanism of Action
Indications
Lead
Discovery
Lead
Optimization
Preclinical
Candidate
IND
Phase I
Phase II
Phase III
Status
BT-1053
2nd-gen BTK
Lymphoma
To be out-licensed
BT-101
2nd-gen TRK
Solid Tumors
To be out-licensed
BT-115
MAT2A
Tumors (Synthetic Lethality)
BT-118
3rd-gen BTK
Lymphoma/Autoimmune Diseases
BT-114
Plasminogen
Hemostasis
BT-119
PKR/EED/PDE9
Rare Diseases
BT-117
Long-acting Radionuclide Drug Conjugates
Platform
BT-123
RNA Splicing
Platform
